Pricing Log in Create free account

Arcturus Therapeutics Holdings Inc. (ARCT) vs Lineage Cell Therapeutics, Inc. (LCTX)

Arcturus Therapeutics Holdings Inc. and Lineage Cell Therapeutics, Inc. are both Biotechnology companies. Arcturus Therapeutics Holdings Inc. is the larger, with a market value of $298.3M against $258.0M — 1.2× the size. Lineage Cell Therapeutics, Inc. grew revenue faster over the last twelve months: 19.9% against −68.7%. Lineage Cell Therapeutics, Inc. has the higher net margin (−246.6% vs −285.9%) and the lower return on invested capital (−186.8% vs 0.00%). Across the 18 metrics below, Arcturus Therapeutics Holdings Inc. leads on 10 and Lineage Cell Therapeutics, Inc. on 8.

Valuation

Metric ARCT LCTX Biotechnology median
P/E n/m n/m 10.60
P/S 9.65 19.45 9.40
P/B 1.74 4.26 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 6.07 15.57 9.02
Earnings yield (29.76%) (14.10%) (32.88%)
Free cash flow yield (21.20%) (9.58%) (23.13%)

Profitability

Metric ARCT LCTX Biotechnology median
Gross margin 100.00% 99.46% 68.51%
Operating margin (311.22%) (205.23%) 0.00%
Net margin (285.91%) (246.58%) 0.00%
Free cash flow margin (204.48%) (186.43%) 0.00%
Return on equity (44.37%) (60.35%) (51.96%)
Return on assets (35.06%) (32.75%) (46.06%)
Return on invested capital 0.00% (186.79%) 0.00%

Growth

Metric ARCT LCTX Biotechnology median
Revenue growth (TTM) (68.74%) 19.87% 6.76%
EPS growth (last fiscal year) 20.00% (211.11%) 29.88%
Revenue growth, 5-year CAGR 53.78% 51.46% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARCT LCTX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.68 6.61 4.97
Net debt to EBITDA 3.15 2.64 1.01

Dividend

Metric ARCT LCTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ARCT LCTX Biotechnology median
Market cap 298.31m 257.97m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack